Human CD117 / c-kit Protein, Fc Tag

INTRODUCTION

QC & Assay Protocol

Citation & Background

Synonym
CD117,SCFR,c-Kit,KIT
Source
Human CD117, Fc Tag (CD7-H5255) is expressed from human 293 cells (HEK293). It contains AA Gln 26 - Thr 516 (Accession # P10721-2).
Predicted N-terminus: Gln 26
Request for sequence
Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 81.9 kDa. The protein migrates as 100-125 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method.
Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
1. 4-8^°C for 12 months in lyophilized state;
2. -70^°C for 3 months under sterile conditions after reconstitution.

SDS-PAGE

Human CD117, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA

Human CD117, Fc TagHuman CD117, Fc Tag (Cat. No. CD7-H5255) ELISA bioactivity

Immobilized Human CD117, Fc Tag (Cat. No. CD7-H5255) at 2 μg/mL (100 μl/well) can bind Mouse SCF, His Tag (Cat. No. SCF-M5228) with a linear range of 0.05-1.2 ng/mL (Routinely tested).

Request for protocol

Immobilized Human SCF, Tag Free (Cat. No. SCF-H4212) at 2 μg/mL (100 μL/well) can bind Human CD117, Fc Tag (Cat. No. CD7-H5255) with a linear range of 0.5-4 ng/mL (QC tested).

Request for protocol

Background
Mast/stem cell growth factor receptor Kit (c-Kit), a member of the protein kinase superfamily, Tyr protein kinase family and CSF-1/PDGF receptor subfamily, is also known as piebald trait protein (PBT), p145 c-kit, tyrosine-protein kinase Kit and CD117,which contains five Ig-like C2-type (immunoglobulin-like) domains and one protein kinase domain. CD117 acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, CD117 can activate several signaling pathways. Furthermore, Activated KIT promotes phosphorylation of the protein phosphatases PTPN6/SHP-1 and PTPRU, and of the transcription factors STAT1, STAT3, STAT5A and STAT5B.
References
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Order Details

CD7-H5255-100ug

Price(USD) : $290.00

CD7-H5255-1mg (500ug × 2)

Price(USD) : $1800.00

Bulk Inquiry Reservation

Development Suggestion

Add to Cart

Promotion & Exhibitions

Fluorescence Labeled CAR-T Target Proteins

PEGS Boston 2018
WPC Boston 2018

CD117 Products

Name：Stem cell growth factor receptor
Classification：Homo sapiens
Number of Launched Drugs：12 Details
Number of Drugs in Clinical Trials：29 Details
Lastest Research Phase：Approved
MORE

Datasheet & Documentation

Contact Us

order@acrobiosystems.com

techsupport@acrobiosystems.com

+1 800-810-0816 (US)

+86 400-682-2521 (AP)

Show All Distributors

New Product Launch

Questions & Comments

English Name	Research Code	Research Phase	Company	First Brand Name	First Approved Country	First Indication	First Approved Company	First Approved Date	Indications	Clinical Trials
Anlotinib Dihydrochloride	AL-3818,ALTN	Approved	Chiatai Tianqing (CTTQ), Advenchen Laboratories	Anlotinib Hydrochloride Capsules	cfda	Non small cell lung cancer (NSCLC)		2018-05-08	Small cell lung cancer (SCLC), Non small cell lung cancer (NSCLC), Soft tissue sarcoma	Details
Ancestim	AMJ-9302	Approved	Amgen, SOBI						Stem cell mobilization	Details
Imatinib mesylate	STI-571; CGP-57148B; CGP-57148; CTI-571; QTI-571,CGP57148B,STI 571,STI571,CGP 57148B	Approved	Novartis	GLEEVEC	fda	Gastrointestinal stromal tumors (GISTs), Chronic myeloid leukemia (CML )	NOVARTIS	2001-05-10	Myelodysplastic syndrome (MDS), Myeloproliferative Disorders (MPD), Gastrointestinal stromal tumors (GISTs), Aggressive systemic mastocytosis (ASM), Hypereosinophilic syndrome (HES), Dermatofibrosarcoma protuberans (DFSP), Chronic eosinophilic leukemia (CEL), Acute lymphoblastic leukaemia (ALL), Chronic myeloid leukemia (CML )	Details
Sorafenib Tosylate	BAY-54-9085; BAY-43-9006; BAY-43-0006; NSC-724772,BAY 43-9006,BAY54-9085,BAY43-9006,BAY 54-9085	Approved	Onyx Pharmaceutical, Bayer	NEXAVAR	fda	Differentiated thyroid cancer, Advanced renal cell carcinoma (RCC), Unresectable hepatocellular carcinoma	BAYER HLTHCARE	2005-12-01	Differentiated thyroid cancer, Renal cell carcinoma, Advanced renal cell carcinoma (RCC), Unresectable hepatocellular carcinoma, Hepatocellular carcinoma (HCC)	Details
Regorafenib Monohydrate	BAY-73-4506; DAST,BAY73-4506,BAY 73-4506	Approved	Bayer, Onyx Pharmaceutical	STIVARGA	fda		BAYER HEALTHCARE PHARMS	2013-02-25	Gastrointestinal stromal tumors (GISTs), Metastatic colorectal cancer (CRC), Hepatocellular carcinoma (HCC)	Details
Lenvatinib Mesylate	E-7080; ER-203492-00,E7080	Approved	Eisai	LENVIMA	fda	Thyroid cancer	EISAI INC	2015-02-13	Differentiated thyroid cancer, Renal cell carcinoma, Advanced renal cell carcinoma (RCC), Thyroid cancer, Unresectable hepatocellular carcinoma, Hepatocellular carcinoma (HCC)	Details
Sunitinib Malate	PNU-290940; SU-11248; SU-010398; SU-011248-L-malate salt; PHA-290940; PHA-290940AD; PNU-290940AD,SU11248,PNU 290940,PNU290940,SU 11248	Approved	Pfizer	SUTENT	fda	Renal cell carcinoma, Gastrointestinal stromal tumors (GISTs), Advanced renal cell carcinoma (RCC), Pancreatic neuroendocrine tumors (pNET)	CPPI CV	2006-01-26	Renal cell carcinoma, Gastrointestinal stromal tumors (GISTs), Advanced renal cell carcinoma (RCC), Pancreatic neuroendocrine tumors (pNET), Renal carcinoma	Details
Ponatinib Hydrochloride	AP-24534; AP24534 HCl; AP24534 hydrochloride; AP24534-HCL,AP 24534,AP24534	Approved	Ariad	ICLUSIG	fda	Acute lymphoblastic leukaemia (ALL), Chronic myeloid leukemia (CML )	ARIAD	2012-12-14	Acute lymphoblastic leukaemia (ALL), Chronic myeloid leukemia (CML )	Details
Cabozantinib S-malate	XL-184; BMS-907351,BMS907351,XL184,XL 184,BMS 907351	Approved	Exelixis, Ipsen, Takeda	COMETRIQ	fda	Medullary thyroid cancer (MTC)	EXELIXIS	2012-11-29	Renal cell carcinoma, Advanced renal cell carcinoma (RCC), Medullary thyroid cancer (MTC), Hepatocellular carcinoma (HCC)	Details
Pazopanib Hydrochloride	GW-786034; GSK-786034; GW-786034B ; SB-786034,GW786034,GW 786034	Approved	GlaxoSmithKline, Novartis	VOTRIENT	fda	Renal cell carcinoma, Soft tissue sarcoma	NOVARTIS PHARMS CORP	2009-10-19	Renal cell carcinoma, Soft tissue sarcoma, Soft tissue infections, Renal carcinoma	Details
Midostaurin	PKC-412; CGP-41231; CGP-41251; PKC-412A,PKC 412,PKC412,CGP41231,CGP 41231,CGP41251,CGP 41251	Approved	Novartis	RYDAPT	fda	Acute myeloid Leukemia (AML), Aggressive systemic mastocytosis (ASM), Systemic mastocytosis with associated hematological neoplasm, Mast cell leukemia	NOVARTIS PHARMS CORP	2017-04-28	Systemic mastocytosis with associated hematological neoplasm, Aggressive systemic mastocytosis (ASM), Acute myeloid Leukemia (AML), Mast cell leukemia	Details
Dasatinib Hydrate	BMS-354825; NSC-732517 ,BMS354825,BMS 354825	Approved	Bristol-Myers Squibb	SPRYCEL	fda	Acute lymphoblastic leukaemia (ALL), Chronic myeloid leukemia (CML )	BRISTOL MYERS SQUIBB	2006-06-28	Acute lymphoblastic leukaemia (ALL), Chronic myeloid leukemia (CML )	Details

English Name	Research Code	Research Phase	Company	Indications	Clinical Trials
Subutinib Maleate		Phase Ⅰ	Chiatai Tianqing (CTTQ), China State Institute of Pharmaceutical Industry (CSIPI)	Gastrointestinal stromal tumors (GISTs), Renal cell carcinoma, Breast cancer, Ovarian cancer, Pancreatic cancer	Details
PLX-9486	PLX-9486; PLX9486,PLX9486	Phase Ⅱ	Daiichi Sankyo	Gastrointestinal stromal tumors (GISTs), Solid tumours	Details
Anti-c-kit humanised IgG1/κ antibody-maitansine conjugate (Novartis)	LOP-628	Phase Ⅰ	Novartis	Solid tumours, Acute myeloid Leukemia (AML)	Details
Famitinib Malate	SHR-1020	Phase Ⅲ	Jiangsu Hengrui Medicine	Gastrointestinal stromal tumors (GISTs), Lung cancer, Liver cancer	Details
Vatalanib succinate	CGP-79787D; PTK-787; ZK-222584,ZK222584,PTK787,CGP79787D	Phase Ⅲ	Novartis, Bayer	Colorectal cancer	Details
Amuvatinib	MP-470; HPK-56,MP470,HPK56	Phase Ⅱ	Astex Pharmaceuticals	Small cell lung cancer (SCLC)	Details
SU-014813	SU-014813; SU-14813; SU-14,813	Phase Ⅱ	Pfizer	Breast cancer	Details
Telatinib	BAY-57-9352; BAY-579352; EOC-315,BAY579352; EOC315	Phase Ⅱ	Bayer, Eddingpharm	Gastric cancer, Gastroesophageal junction adenocarcinoma	Details
Golvatinib/Lenvatinib		Phase Ⅱ	Eisai	Glioblastoma, Angiomas, Melanoma	Details
Tafetinib Malate	SIM-010603; SIM-0702; SIM-1005,SIM010603	Phase Ⅰ	Simcere, BolDere Pharma, Nanjing Yoko Biological	Colon cancer, Non small cell lung cancer (NSCLC), Gastrointestinal stromal tumors (GISTs), Renal cell carcinoma, Breast cancer, Liver cancer, Ovarian cancer	Details
Tandutinib	MLN-0518; MLN-518; CT-53518,MLN0518,MLN518,CT53518	Phase Ⅱ	Takeda	Renal cell carcinoma, Acute myeloid Leukemia (AML)	Details
QBH-196	QBH-196	Phase Ⅰ	Shenyang Pharmaceutical University	Gastric cancer	Details
Imatinib mesylate (YD Global Life Science)	YD-312	Phase Ⅱ	YD Global Life Science	Diabetic macular edema	Details
Dovitinib Lactate	CHIR-258; GFKI-258; CHIR-258LC; TKI-258; NVP-TKI258,GFKI258,CHIR258,TKI258	Phase Ⅲ	Novartis	Renal cell carcinoma, Solid tumours	Details
Motesanib Diphosphate	AMG-706,AMG706,AMG 706	Phase Ⅲ	Amgen, Takeda	Advanced non-squamous non small cell lung cancer (NSCLC)	Details
QLNC-3A6 Di-Maleate		Phase Ⅰ	Qilu Pharmaceutical, Qilu Antibiotics (Linyi) Pharmaceutical	Solid tumours	Details
Masitinib mesylate	AB-1010,AB1010,AB 1010	NDA Filing	AB Science	Gastrointestinal stromal tumors (GISTs), Prostate cancer, Multiple myeloma (MM)	Details
AKN-028	AKN-028; BVT-II; BVT63628 ,AKN028,BVTII,BVT63628	Phase Ⅱ	Akinion	Acute myeloid Leukemia (AML)	Details
Pexidartinib Hydrochloride	PLX-3397,PLX3397	Phase Ⅲ	Daiichi Sankyo	Tenosynovial giant cell tumor (TGCT), Pigmented villonodular synovitis	Details
IGN-311	IGN-311	Phase Ⅰ	PDL BioPharma, Celltrion	Cancer	Details
Hydroxychloroquine/Sorafenib		Phase Ⅰ	VG Life Sciences	Solid tumours, Ovarian cancer	Details
Donafenib Tosylate	CM-4307,CM4307	Phase Ⅲ	Zelgen Biosciences	Differentiated thyroid cancer, Colorectal neoplasms, Hepatocellular carcinoma (HCC)	Details
Avapritinib	BLU-285,BLU285	Phase Ⅲ	Blueprint Medicines, CStone Pharmaceuticals	Gastrointestinal stromal tumors (GISTs), Solid tumours	Details
Thiophenib Tosylate	SIM-81; OSI-930	Phase Ⅰ	Astellas, Simcere	Small cell lung cancer (SCLC), Gastric cancer, Non small cell lung cancer (NSCLC), Colorectal neoplasms, Gastrointestinal stromal tumors (GISTs), Esophagus cancer, Ovarian cancer, Head and neck cancer, Malignant glioma	Details
XL-820	XL-820	Phase Ⅱ	Exelixis	Gastrointestinal stromal tumors (GISTs)	Details
mSCF-based gene therapy (Celladon)		Preclinical	Celladon	ischaemic heart disorder	Details
DCC-2618	DCC-2618; ripretinib,DCC 2618;DCC2618	Phase Ⅲ	Deciphera	Gastrointestinal stromal tumors (GISTs), Aggressive systemic mastocytosis (ASM), Malignancies	Details
AG-2034	AG-2034; AGL-2034	Phase Ⅰ	Yissum	Solid tumours	Details
EXEL-0862	EXEL-0862	Preclinical	Exelixis	Cancer	Details